Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS, Douros JD, Gabe MB, Showalter AD, Wainscott DB, Suter TM, Capozzi ME, van der Velden WJ, Stutsman C, Cardona GR, Urva S, Emmerson PJ, Holst JJ, D'Alessio DA, Coghlan MP, Rosenkilde MM, Campbell JE, Sloop KW.
Willard FS, et al.
JCI Insight. 2020 Sep 3;5(17):e140532. doi: 10.1172/jci.insight.140532.
JCI Insight. 2020.
PMID: 32730231
Free PMC article.